{"entity":{"id":"nct07554521","kind":"trial","name":"A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States","aka":[],"tldr":"A phase 2 trial of Tislelizumab, Capecitabine, Fluorouracil (5-FU) and Oxaliplatin in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by BeOne Medicines, now recruiting.","summary":"A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States is a phase 2 interventional study registered as NCT07554521 by BeOne Medicines, with 30 participants planned, started 2026-04-30 and due to reach its primary completion in 2031-12-31. Interventions recorded: Tislelizumab, Capecitabine, 5-fluorouracil (5-FU), Oxaliplatin and Leucovorin.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07554521","url":"https://clinicaltrials.gov/study/NCT07554521"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":["tislelizumab","capecitabine","fluorouracil","oxaliplatin"],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07554521","phase":"2","setting":"An Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Tislelizumab Plus Chemotherapy in a First-Line Setting for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in US Racial and Ethnic Minority Patients","sponsor":"BeOne Medicines","enrolled":30,"outcomes":[]},"route":"/trials/nct07554521/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}]}}